Wall Street analyst estimates for Hepion Pharmaceuticals, Inc. (HEPA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 3 |
| Avg rating (1-5) | 0.33 |
Valuation Ratios
| Price / Book | 0.88 |
| EV / EBITDA | 0.34 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | $21938 | $18787 | $26737 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -$21938 | -$18787 | -$26737 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $13.7M | $14.3M | $7.6M | $3.2M | $12.0M | $20.4M | $33.3M | $35.6M | $11.8M | $445512 |
| Selling, General & Admin | $7.4M | $6.7M | $7.0M | $4.6M | $8.1M | $10.0M | $10.3M | $9.6M | $7.5M | $3.3M |
| Operating Expenses | $21.0M | $21.0M | $14.6M | $7.8M | $20.1M | $30.4M | $45.5M | $48.4M | $19.3M | $4.2M |
| Operating Income | -$21.0M | -$21.0M | -$14.6M | -$7.8M | -$20.1M | -$30.4M | -$45.5M | -$48.4M | -$19.3M | -$4.2M |
| EBITDA | -$21.0M | -$20.6M | -$14.6M | -$7.7M | -$20.1M | -$32.6M | -$45.0M | -$49.3M | -$14.9M | -$3.7M |
| Interest Expense | 0 | 0 | $339158 | $554998 | $31229 | $8859 | $10164 | $9465 | $1.2M | $24406 |
| Pre-tax Income | -$16.8M | -$18.9M | -$10.0M | -$7.9M | -$20.3M | -$32.7M | -$45.1M | -$49.3M | -$16.2M | -$8.3M |
| Income Tax | -$1.9M | -$3.9M | -$536000 | -$908682 | $30584 | 0 | -$2.9M | -$409022 | -$3.0M | 0 |
| Net Income | -$14.9M | -$15.0M | -$9.4M | -$7.0M | -$20.4M | -$32.7M | -$42.2M | -$48.9M | -$13.2M | -$8.3M |
| EPS | $-2855.94 | $-106400.00 | $-97353.00 | $-6108.07 | $-2103.70 | $-465.52 | $-594.75 | $-616.07 | $-107.35 | $-0.88 |
| EPS (Diluted) | $-3373.93 | $-106400.00 | $-97353.00 | $-6108.07 | $-2103.70 | $-465.52 | $-594.75 | $-616.07 | $-107.35 | $-0.88 |
| Shares Outstanding (Diluted) | $5208 | $138 | $184 | $2043 | $9677 | $70291 | $76229 | $79416 | $122894 | $9.4M |
Price
| Price | $0.07 |
| Market Cap | $1M |
| Exchange | OTC |
| Country | US |
Related companies: CDT · COCH · ENVB · LIXT · NIVF · PTPI · SRZN
Explore sector: Healthcare · Biotechnology
More sections of HEPA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks